IGB archive

Dr Reddy′s bullish on China

India Global Business Staff

With incipient regulatory changes in China on Indian drug imports, Dr Reddy′s Laboratories has identified about 70 products for the country to be launched in a few years and is also planning to build a new plant very close to the existing one. Erez Israeli, COO, Dr Reddy′s, said the drug-maker is in the process of seeking necessary approvals from Chinese authorities for selling drugs including in oncology area there and is upgrading professional teams for the growth. He said: "China is an important space for us and we see a major opportunity in China. As China opened, especially with the changes of regulations to the kind of products in terms of quality and cost-effective that we can build to China. "We are upgrading our team in China and we are also going to build a new plant very close to the current plant that we have. So overall, very exciting opportunities.” Recently, India has identified and shared with China a list of 380 products, including horticulture, textiles, chemicals and pharmaceutical products, as their shipments hold huge export potential.

In a move that renewed hope in India’s civil aviation circles, and sent waves of optimism in business circles, the Tata Group acquired beleaguered national carrier Air India for $2.4 billion last week. The transaction will be completed by December 2021.

Tata Group’s take over of Air India puts the competition on alert

RBI says growth impulses strengthening, inflation trajectory favourable

Gadkari focuses on alternate fuels, EVs in clean transport push

India, UAE march towards Comprehensive Economic Partnership Agreement

India’s new Parliament on track to host 2022 Winter Session